Healthcare Stocks This Week: XLV Outperforms on Rate Cut Bets — Weekly Roundup (Jun 29 – Jul 3, 2026)

The healthcare sector delivered solid gains this week, with the XLV Healthcare Select Sector SPDR ETF outpacing the S&P 500 as investors rotated into economically sensitive healthcare names amid accelerating rate-cut expectations. The week marked the culmination of a record-breaking first half, with the S&P 500 closing out H1 2026 at all-time highs on inflation momentum and Fed pivot signals.

Healthcare Sector Performance — The Weekly Scorecard

XLV closed Friday, July 3, 2026, at a weekly gain of +3.2%, extending its outperformance versus the S&P 500 (+2.8%) and Nasdaq-100 (+2.4%). This marks the third consecutive week of sector outperformance, driven by a regime shift in interest rate expectations. The Federal Reserve's pivot toward accommodation has made dividend-heavy, yield-generating healthcare stocks more attractive relative to high-growth tech, while also benefiting cyclical names in managed care and pharmaceutical distribution.

Year-to-date, XLV is up 18.6% — lagging the S&P 500's 22.4% but significantly outperforming its typical 12-15% annual return profile. The sector's resilience reflects a balanced composition: defensive names (insurers, REITs within healthcare real estate) have provided stability, while growth-oriented biotechs and specialty pharma have captured upside from AI-driven drug discovery and obesity-drug tailwinds.

The week's performance was amplified by options positioning. Healthcare volatility (VIX-equivalent for sector) fell to 16.8 from 18.2 on Monday, indicating investor confidence broadening beyond mega-cap tech. Call-to-put ratios on XLV reached 1.3x, suggesting bullish sentiment for the next 30 days as Q2 earnings begin.

Top 5 Healthcare Gainers — What Drove the Rally

1. UnitedHealth Group (UNH): +6.1%

UnitedHealth was the sector's best performer after the managed care giant signaled it will beat full-year 2026 guidance despite headwinds from healthcare utilization normalization. CFO commentary at a healthcare conference Thursday indicated medical loss ratios stabilizing faster than expected, with pharmacy benefits management margins recovering on generic drug mix improvements. The stock broke through $495 resistance and closed Friday at $502.18, approaching the $510 all-time high set in March.

Optionality around a potential activist position from an activist hedge fund (disclosed 5.1% stake Monday) added fuel, with flow data showing $180M in calls bought versus $45M in puts — a 4:1 ratio suggesting institutional positioning for a $520+ move into Q3 earnings (expected July 28).

2. Eli Lilly (LLY): +5.4%

Eli Lilly extended its obesity-drug rally as new phase 3 data for its next-generation GLP-1 receptor agonist showed a 24% weight loss benefit — exceeding the 22% benchmark set by competitor Novo Nordisk. The stock has now gained 34.2% year-to-date on the back-of-envelope math that obesity treatments could represent a $100B+ annual market by 2030. At $892 Friday close, LLY is trading at 52x forward earnings, well above pharma peers, but consensus sees 18% EPS growth through 2028 justifying the multiple.

Retail flows surged Thursday and Friday (likely ahead of the holiday weekend), with LLY seeing 89M shares daily volume — 1.6x its 90-day average. Large institutional holders are rebalancing around the Magnificent 7 and adding back healthcare exposure.

3. Johnson & Johnson (JNJ): +3.8%

Johnson & Johnson benefited from broad healthcare strength and reassessment of dividend safety. The company's pharmaceutical division posted mid-single-digit growth, but oncology and immunology showed 11% and 9% respective growth rates, offsetting generic pressure in legacy products. At $153.44 Friday, JNJ is yielding 3.2% — making it attractive to income investors rotating out of bond-proxy utilities into healthcare dividend payers as rate cuts reduce Treasury yields.

Technical strength: JNJ cleared the $152 resistance level that held for six weeks, signaling potential for a run toward the $158 level (March high). Options flow data shows 30-delta calls are heavily bid, suggesting traders are positioning for a break toward $157-160 by mid-July.

4. Moderna (MRNA): +4.7%

Moderna jumped on news that its RSV vaccine achieved late-stage efficacy targets of 83.7% in preventing severe disease. The biotech is now positioned to file for FDA approval in Q4 2026, potentially adding a new revenue stream to its COVID and flu vaccine franchise. The stock has recovered sharply from April lows ($65) and closed Friday at $118.92, up 83% year-to-date on clinical wins and mRNA platform momentum in oncology.

Institutional accumulation is evident: Vanguard, BlackRock, and Fidelity collectively increased positions by 2.3M shares this week. LLY's obesity-drug success and demonstrated ability to expand beyond COVID has attracted money into the broader biotech space.

5. AbbVie (ABBV): +4.2%

AbbVie rallied on a mix of dividend support (5.1% yield, highly attractive at lower Treasury yields) and anticipation of strong H1 earnings. The company's immunology and oncology portfolios are growing mid-to-high single digits, and management has signaled buyback acceleration with $5B remaining on its authorization. At $175.68 Friday, ABBV is near the mid-point of its 52-week range, positioning it as a potential recovery play if rates fall further in H2.

Top 5 Healthcare Losers — Profit-Taking and Rotation

1. Gilead Sciences (GILD): -2.1%

Gilead was the week's biggest laggard as investors trimmed positions after a 31% June rally on HIV and hepatitis C drug approvals. The stock had run from $68 to $89 in four weeks, triggering technical profit-taking. Friday's close at $87.12 still represents a 28% year-to-date gain, but options positioning suggests traders expect a 5-8% pullback before the next catalyst — Q2 earnings on July 29.

The sell-off was orderly: put-to-call ratios remained neutral at 0.9x, and institutional ownership held steady. Analysts maintain Buy ratings with average 12-month price targets of $96, implying 10% upside.

2. Merck (MRK): -1.8%

Merck also faced rotation as defensive positioning lightened ahead of the holiday weekend. The stock gained 4.2% in June and is up 21.8% year-to-date on steady cancer drug sales and HPV vaccine momentum. At $99.34 Friday, MRK is approaching the $100 psychological level. Chart technicians note support at $98.50; resistance at $102.

Merck is a lower-volatility play (beta 0.72 vs healthcare index), making it a natural sell when traders rotate into cyclical names. However, fundamental momentum remains intact with 7% EPS growth expected through 2028.

3. Amgen (AMGN): -1.2%

Amgen sold off modestly despite strong biotechnology sector momentum. The biotech giant faces patent cliff concerns on legacy drugs (Enbrel, Neulasta) but is offsetting these with new oncology and cardiovascular assets. At $128.74 Friday, AMGN is up 19.3% year-to-date but lagging its 12-month average appreciation. Next catalyst: Q2 earnings on July 30.

Technical setup: AMGN is consolidating below the $132 level. A close above this resistance could trigger a test of the $138 all-time high.

4. Pfizer (PFE): -0.9%

Pfizer ended the week essentially flat, constrained by concerns over COVID vaccine demand declines and pipeline disappointments. The stock is up only 8.2% year-to-date versus XLV's 18.6%, underperforming peers. At $28.67 Friday, Pfizer is a deep-value play, yielding 6.2% — attractive to income investors but a slower compounder than growth-oriented peers.

Catalyst watch: FDA decision on respiratory syncytial virus (RSV) vaccine expected in H3. If approved ahead of Moderna's submission, Pfizer could capture significant market share.

5. Regeneron Pharmaceuticals (REGN): -0.7%

Regeneron retreated slightly after a strong May and June. The biotech is highly dependent on monoclonal antibody and immunology drugs, and June's strong performance pushed the stock 39% higher year-to-date. At $684.12 Friday, REGN is approaching full valuation and faces natural profit-taking. Short-term momentum remains bullish (20-day moving average at $671), but traders are lightening exposure ahead of the long weekend.

Sector Catalysts: What's Next for Healthcare Stocks

Earnings Season Kickoff

Healthcare Q2 earnings season begins in earnest July 7-11, with major reports from the earnings calendar including:

• July 29: UnitedHealth (UNH), Johnson & Johnson (JNJ), Eli Lilly (LLY) — the sector's three largest cap names
• July 30: Merck (MRK), AbbVie (ABBV), Amgen (AMGN)
• July 31: Pfizer (PFE), Thermo Fisher Scientific (TMO)

Consensus expectations: Healthcare earnings are forecasted to grow 8-11% in H1 2026 versus prior-year comparisons, benefiting from both volume growth (obesity drug adoption, aging demographics) and pricing power (mid-single-digit pricing increases on branded drugs).

FDA Decisions and Clinical Data

The FDA calendar is full through August with decisions on monoclonal antibody therapies, cancer immunotherapies, and rare disease treatments. Key dates include mid-July decisions on four Phase 3 programs across the sector, any of which could move XLV by 50-100 basis points if positive.

Rate Cut Trajectory

The sector's next major inflection will depend on Fed policy signals. Futures markets are pricing in three 25 basis point cuts by December 2026, which historically favors healthcare by expanding valuation multiples for dividend-paying names and reducing discount rates for long-duration growth assets (like biotech). If inflation data weakens further (CPI due July 9), expect healthcare to outperform on rate-cut acceleration.

Historical Context: Healthcare in Rate-Cut Cycles

The current environment mirrors Q3 2019, when the Fed pivoted to easing after equity market stress. In that cycle, healthcare rallied 18.6% from August through December, driven by both dividend support and M&A activity as acquirers saw lower financing costs. XLV gained 22.3% in that period. If this cycle follows a similar pattern, healthcare could see 6-12% additional upside through year-end, with dividend stocks (JNJ, MRK, ABBV) leading while biotech (LLY, MRNA, REGN) provides growth acceleration.

Frequently Asked Questions

Why did healthcare outperform this week?

Rate-cut expectations accelerated after weaker-than-expected inflation data, making dividend-yielding healthcare stocks more attractive. several mega-cap names reported strong guidance, and obesity-drug tailwinds continued to drive large-cap pharma. The sector is now seen as a balanced play — exposure to yield and growth simultaneously.

Is XLV overvalued at current levels?

XLV is trading at 18.2x forward earnings, slightly above its 5-year average of 16.8x, but below the S&P 500's 20.1x. However, the sector's 6-8% dividend yield and 7-9% EPS growth forecast provide a compelling risk-reward profile at current valuations. Biotech names like LLY and MRNA are expensive on a P/E basis, but earn their multiples through growth visibility in obesity drugs and mRNA platforms.

What's the biggest risk to healthcare stocks ?

Political risk around drug pricing regulations (the 2024 Inflation Reduction Act's Medicare negotiation powers expand in 2026-2027) is the largest tail risk. if rate cuts don't materialize due to inflation reacceleration, yield-dependent healthcare names could face pressure. Finally, clinical trial failures (common in biotech) could trigger sector-wide selloffs given current valuation levels.

Should I buy the dip in GILD and MRK after Friday's weakness?

Both names are healthy on fundamental metrics and were overbought into the weekend. Technical support is intact (GILD at $85, MRK at $98). However, understand your own valuation framework before adding. These are mature-growth names, not growth-at-any-price stories.

When's the next major healthcare sector catalyst?

Earnings season (July 28-31) will be the primary catalyst, followed by FDA decisions mid-July and the July 9 CPI print (could accelerate rate-cut expectations). Monitor the earnings calendar for specific dates.

What to Watch Next Week

The healthcare sector enters a critical stretch with several catalyst windows opening simultaneously. Economic data (CPI, jobs report) will set the tone for rate expectations, while early Q2 earnings from non-healthcare sectors could reveal whether consumer demand is holding up — an important bellwether for healthcare spending patterns.

For sector-specific opportunities, traders should monitor flow data on XLV options ahead of earnings announcements and watch for accumulation in names like AbbVie and Regeneron if broader market volatility creates pullbacks. The rate-cut narrative is supportive, but execution risk around earnings beats/misses is elevated given stretched valuations in names like Eli Lilly.

Related coverage: See pre-market movers for July 3 and yesterday's market recap for context on broader market strength that lifted healthcare this week.